Biopharmaceutical group CSL isn’t happy with its performance after reporting a big fall in interim earnings, a day after its chief executive’s shock retirement.
Biotech giant posts profit slump after CEO's shock move
Biopharmaceutical group CSL isn’t happy with its performance after reporting a big fall in interim earnings, a day after its chief executive’s shock retirement.